Background. Genetic risk for bipolar disorder (BD) is conferred through many common alleles, while a role for rare copy number variants (CNVs) is less clear. BD subtypes schizoaffective disorder bipolar type (SAB), bipolar I disorder (BD I) and bipolar II disorder (BD II) differ according to the prominence and timing of psychosis, mania and depression. The factors contributing to the combination of symptoms within a given patient are poorly understood.
INTRODUCTION
Classically conceptualized as an episodic mood disorder with alternating periods of mania and depression, the diagnosis of bipolar disorder (BD) encompasses heterogeneous clinical presentations that vary with respect to symptomatology 1,2 , comorbidity 3 and longitudinal course 4 . There are 3 diagnoses on the BD spectrum in current classifications of mental illness 5, 6 : bipolar I disorder (BD I), bipolar II disorder (BD II) and schizoaffective disorder bipolar type (SAB). The criteria for these diagnoses differ from one anotherand from clinically related diagnoses such as schizophrenia (SCZ) and major depressive disorder (MDD)by nuances in the prominence and timing of manic, depressive and psychotic symptoms. An episode of mania equates to a diagnosis of BD I unless (1) the episode includes psychotic symptoms and (2) there is also a history of psychosis for at least 2 weeks in the absence of mania, in which case SAB is diagnosed. A history of hypomania and depressive episodes equates to a diagnosis of BD II. However, if psychosis occurs during an otherwise hypomanic episode, then the episode is considered manic (and the diagnosis BD I). Psychosis during a depressive episode does not preclude a diagnosis of BD II, so long as the individual has never met the criteria for mania. These nuances are subject to change across versions of the same system of classification 5, 7, 8 and the factors determining the combination of symptoms that occur in a given patient remain poorly understood.
BD genetic risk is conferred through many common single-nucleotide polymorphisms (SNPs) of small effect across the genome 9 , many of which also confer risk to clinically related psychiatric conditions 10, 11 . The overlap between BD and SCZ is particularly high in this regard, with genetic correlation estimates between the two (rg = 0.6 -0.7) comparable to estimates between BD I and BD II (rg = 0.7 -0.8) [9] [10] [11] [12] . In contrast, rare variants in particular, rare copy number variants (CNVs)have not been consistently implicated in risk for BD 13, 14, [23] [24] [25] [26] [15] [16] [17] [18] [19] [20] [21] [22] , unlike in SCZ where an increased burden of rare CNVs is well-established 20, 22, 27, 28 . The largest genomewide study of rare CNVs in BD to date found no differences in burden between approximately 2,600 cases and 8,800 controls 13 . Smaller studies have been inconsistent, with some finding a decreased burden in BD 21, 22, 29 and others a modest increase when stratifying cases according to certain clinical criteria. For instance, CNV burden in early-onset BDa focus of such studies due to the increased CNV burden in neurodevelopmental disorders 25 has been found by some 15, 16, 20, 26 but not others 17, [21] [22] [23] . Specific CNVs implicated in SCZ and neurodevelopmental disorders have been tested for association with BD, and a duplication of 16p11.2 implicated in SCZ 30 was recently reported to be enriched in BD 13 . Tested as a set rather than individually, these psychiatric CNVs are not significantly enriched in BD 21, 22, 26 , nor have CNVs in BD consistently been found enriched for particular biological pathways or gene sets [15] [16] [17] 26 . In total, the evidence that rare CNVs contribute to BD risk broadly is limited.
There is mounting evidence suggesting that the common alleles conferring risk to BD and SCZ act at the symptom level 31, 32 , rooting the clinical similarity of BD and SCZ at least partially in common genetic variation. In contrast, the relative absence of rare CNV burden in BD 13 raises the possibility that this class of variation confers risk to clinical phenomena more commonly associated with SCZ. Such phenomena could include both the nuances in the prominence and timing of psychotic symptoms that formally differentiate SCZ and BD diagnostic criteria 5, 6 , as well as non-diagnostic features such as differences in cognitive deficits 33 and clinical course that historically formed the basis for the dichotomization of BD and SCZ 34, 35 . Indeed, studies of psychiatric CNVs in the general population have demonstrated an effect on cognitive performance 33, 36 . Profiling rare CNVs and common risk alleles in BD cases stratified by granular clinical data would provide the opportunity to more directly test whether these classes of genetic variation make differential contributions to particular psychiatric traits. To our knowledge, such studies are lacking.
Here, we present results on a genome-wide study of CNVs in BD (6,353 cases and 8,656 controls), approximately a 2.5-fold increase in case sample size from the previous largest such study 13 . In addition to a comprehensive assessment of genome-wide CNV burden between BD and controls, we assess the contribution of rare CNVs and common SCZ risk alleles to risk of psychosis, a clinical phenomenon that differentiates BD subtypes from one another and from SCZ.
METHODS AND MATERIALS

Sample Description
The International Cohort Collection for Bipolar Disorder (ICCBD) includes BD cases and unaffected controls from the Sweden Bipolar Disorder Cohort (SWEBIC), the Bipolar Disorder Research Network (BDRN) in the United Kingdom, and the Genomic Psychiatry Consortium (GPC) from the University of Southern California. Full ICCBD sample descriptions have been previously reported in a genome-wide association study (GWAS) 12 . The BDRN controls were collected as part of the Wellcome Trust Case Control Consortium; half were utilized in a genome-wide CNV burden analysis with a set of BD cases not in the current study 22 , and the other half in a separate genome-wide CNV analysis 13 . The subset of the SWEBIC cases and controls genotyped on the Affymetrix platform were in a previous report of genome-wide CNV burden in BD 20 . Genome-wide CNV burden has not been reported before for the GPC cohort or for the SWEBIC cases and controls genotyped on the Illumina platform (45% of ICCBD cases in this study).
Phenotyping methods
Full descriptions of the approaches utilized in the phenotyping of the ICCBD cohorts have been reported previously 12, 37 . For some analyses in this report, clinical variables beyond case-control status were included from all 3 ICCBD sites, including age of onset, history of psychosis and family history. Age of onset was defined as the age at which first symptoms, impairment or diagnosis occurred. Psychosis was defined as the lifetime presence of hallucinations or delusions. Family history was defined as having any family member with any psychiatric diagnosis. For each variable, a set of standardized numerical values were derived, and site investigators harmonized datasets according to these metrics. This was necessary to facilitate analysis across sites that used different phenotyping approaches (Supplementary Material).
Genotyping and ancestry covariates
Sample collection and genotyping procedures for the ICCBD have previously been reported 12 . In brief, for all ICCBD sites DNA was extracted from peripheral blood samples that had been collected and stored at -20 o C. Samples were then genotyped at the Broad Institute, and genotypes were called using either Birdsuite (Affymetrix) or BeadStudio (Illumina). Genotypes were generated as sufficient numbers of samples accumulated from field work. Ancestry covariates were derived from the genotyping data through multidimensional scaling (MDS) analysis on genome-wide identity-by-descent distances calculated for all pairs of individuals. Full details on the quality control procedures implemented to derive the genotype calls utilized in this report have been previously described 12 .
CNV calling and quality control
Rare CNVs were identified using the Birdseye program in Birdsuite 38 , which is based on a hidden Markov model. For each CNV, a logarithm of the odds ratio (LOD) score was generated that describes the likelihood of a CNV relative to no CNV over a given interval including flanking sequences. Only subjects who passed quality control filters in an earlier GWAS of the same individuals 12 were considered for CNV analyses. CNVs were excluded if any of the following criteria were met: LOD score < 10, number of probes < 10, probe density of < 1 per 20 kilobases (KB), frequency in ICCBD > 1%, or location within a region known to contain common CNVs or large genomic gaps (e.g., centromeres). If in a given individual the distance between two CNVs was less than 20% of their combined size, they were considered artificially split by the calling algorithm and combined into a single event. For the BDRN cohort, only genomic regions covered in both cases and controls were retained in order to reduce batch effects resulting from cases and controls being genotyped on different Illumina arrays (Supplementary Material). Subjects were removed for having total CNV number greater than two standard deviations different from the mean number of CNVs in the cohort (prior to applying filters for CNV frequency). These quality control checks were performed separately for the SWEBIC Affymetrix, SWEBIC Illumina, BDRN, and GPC cohorts ( Table 1) .
Unless otherwise specified, burden analyses were restricted to autosomal CNVs >100kb. Two events were considered equivalent for the purposes of defining frequency if one overlapped the other by at least 50%. In the context of burden analyses, we use the term "CNV" to refer to the combined set of deletions and duplications, and "singleton CNVs" were defined as any event that occurred once in the full ICCBD casecontrol cohort without consideration of whether the event was a deletion or a duplication. Specific singleton deletions and duplications were defined after first filtering the dataset for that type of event. As such, not all singleton deletions and duplications are in the singleton CNV group.
CNV burden tests
For our primary analyses, we defined CNV burden in 3 ways: the number of CNVs occurring per individual (the CNV number); the number of genes lying within CNVs per individual (the CNV gene count); the total distance covered by CNVs. We elected to focus on these 3 classes of burden because there is no clear class of burden most relevant to BD and these classes significantly differed between cases and controls in the largest SCZ CNV study to date 27 . We stratified CNVs by 3 types: deletions only, duplications only, deletions and duplications (or "CNVs"); by 2 sizes: over 100KB and over 500KB; and by 2 frequencies: singletons and those occurring in less than 1% in the ICCBD (a frequency of 6.7 x 10 -5 ). This led to 36 tests between each pair of phenotypes we compared, of which there were 7: (1) BD cases to controls, (2) BD I cases to controls, (3) BD II cases to controls, (4) SAB cases to controls, (5) BD I cases to BD II cases, (6) BD I cases to SAB cases, and (7) BD II cases to SAB cases. Therefore, in total, there were 252 tests in our primary assessment of CNV burden.
Previous studies of CNV burden in BD have reported nominally significant results (p-value < 0.05) for tests where the definition of burden fell outside the scope of the 252 tests in our primary burden assessment.
Through manual curation of the literature, we identified 34 unique associations (2 were observed in 2 separate studies). We were able to test 27 of these in the ICCBD data (for the other 7, the original study included either SCZ cases or BD parent-child trios), of which 21 included a burden class not assessed in our primary 252 tests. In some instances, the dataset used in the original paper overlapped that used in this report, in which case the overlapping samples were excluded from the test.
We also tested ICCBD CNVs, filtered for size over 100KB and frequency <1%, for enrichment of sets of CNVs previously identified in studies of BD, SCZ or neurodevelopmental disorders. The BD CNV set (16 deletions, 14 duplications) was derived by merging overlapping autosomal de novo CNVs from 3 previous studies of BD trios 16, 17, 24 . The SCZ CNV set was comprised of autosomal CNVs with suggestive evidence for association in a meta-analysis of over 20,000 SCZ cases and 20,000 controls (11 deletions, 8 duplications) 27 . The neurodevelopmental CNV set was derived from a list curated for a previous report 17 for which CNVs overlapping those in the SCZ set had been removed (27 deletions, 18 duplications) . In order for a CNV in the test set to be considered overlapping with an ICCBD CNV, the ICCBD CNV was required to cover at least 50% of the test CNV and be of the same CNV type (i.e., deletion or duplication).
All tests were performed using permutation in PLINK 39 controlling for genotyping platform and ICCBD site. Significance was evaluated using 10,000 permutations. The 252 tests in the primary assessment were 2sided with the exception of 6 tests that had previously been reported as significant. A one-sided test in the direction of the association reported in the original paper was used for these 6 tests as well as for the additional 21 tests following up previous associations and the 3 tests of CNV sets. To account for multiple testing, we considered as study-wide significant any result surpassing correction for 276 tests (252 primary burden tests, 21 tests of previous burden associations, 3 tests of CNV sets). At a 5% false discovery rate (FDR), an empirical p-value below 0.002 was considered study-wide significant.
Contribution of CNV burden and SCZ PRS to psychosis
Following results from our primary burden analyses, we analyzed CNV burden and loading of common SCZ risk alleles in BD I and SAB cases. BD II was excluded from these analyses to remove effects resulting from known differences in polygenic loading of SCZ alleles across BD subtypes 12 . For these analyses, burden was defined as the number of CNVs greater than 500KB and present in less than 1% of the study sample. We focused on this one burden definition here because it was the only class in our primary assessment of burden where an increase was seen in SAB compared to controls, BD I and BD II (see Results). For these analyses, burden was tested using logistic regression, which returned similar results to permutation but allowed us to include in the model continuously-distributed ancestry covariates and facilitated the calculation of odds-ratios (ORs) for CNV burden 27 . In the regression model, we used phenotype status as the dependent variable and CNV burden as an independent predictor variable. The OR is the exponential of the logistic regression coefficient, and OR > 1 represents increased risk for the "affected" phenotype in the model, which was designated to be the phenotype more clinically similar to SCZ. Using a similar regression model, we carried out polygenic scoring analyses 40 . Quantitative polygenic risk scores (PRS) were computed for each case subject based on the set of SNPs with p-values less than 0.5 in the second SCZ GWAS from the Psychiatric Genomics Consortium (PGC) 41 . PRS analyses excluded ICCBD samples present in the PGC studies and ICCBD SWEBIC Affymetrix cases due to lack of a control cohort once PGC overlaps were removed. Effect sizes for both CNV burden and SCZ PRS were calculated as a t-statistic that is the ratio of the coefficient of the burden or PRS variable and its standard error from a generalized linear regression model equation. As studies of SCZ have consistently demonstrated higher CNV burden in cases compared to controls 27, 28 , cases were stratified by clinical dimensions related to SCZ (i.e., psychosis) and 1-sided statistical tests were used evaluating for higher rates in groups with the more SCZ-like phenotype.
RESULTS
CNV burden in BD
We assessed genome-wide differences in rare CNV burden between 6,353 BD cases and 8,656 controls ( Table 1) . After initial filters for size (> 100KB) and frequency (occurring in < 1% of ICCBD), we observed 10,515 CNVs (3,970 deletions and 6,545 duplications). No difference in the CNV number was found between cases and controls (case rate = 0.698, control rate = 0.702, p-value = 0.86). This was true both for deletions (case rate = 0.266, control rate = 0.264, p-value = 0.78) and duplications (case rate = 0.433, control rate = 0.439, p-value = 0.72). Similarly, no differences were observed between cases and controls with respect to the number of genes hit or the total distance covered by CNVs ( Table 2) .
Following previous literature showing that rarer and larger CNVs carry increased burden for neuropsychiatric illness 28 , we further filtered CNVs by size (> 500KB) and frequency (those that occur once in the 15,009 ICCBD individuals, a frequency of 6.6 x 10 -5 ). No test was significant below our study-wide p-value threshold ( Table 2 ) that accounts for 276 genome-wide burden tests at FDR 5% (see Methods). A report on CNV burden for the SWEBIC Affymetrix sample (917 cases, 1,1670 controls) previously noted a significant increase in the number of CNVs in BD cases compared to controls 20 . To assess whether nominally significant associations ( Table 2) were driven by these previously reported observations, we repeated these analyses after excluding the SWEBIC Affymetrix cohort and no tests remained nominally significant (Supplementary Material).
Previous reports of CNV burden in BD have found nominally significant associations across several classes of burden beyond those assessed above. We curated the literature to identify all previous associations of BD and CNV burden of at least nominal significance (p-value < 0.05) in the initial report. We found 34 unique associations, of which we could test 21 that were not included as part of our primary assessment of burden (see Methods). None of these tests surpassed study-wide significance p-value threshold of 0.002 (Figure 1; Table 3 ).
We next sought to assess CNVs previously implicated in psychiatric diseases for contribution to BD risk. We compiled CNVs from previous reports into 3 lists: a BD set based on de novo CNV events observed in BD trios 16, 17, 24 ; a SCZ set derived from a study of over 20,000 SCZ cases and 20,000 controls 27 , and a set comprised of CNVs previously implicated in neurodevelopmental disorders 17 . The latter two sets shared a subset of regions but were treated as independent sets after accounting for the overlap (see Methods). Neither the BD nor SCZ sets were enriched for deletions or duplications in cases compared to controls. A nominal enrichment that did not survive correction was noted for the neurodevelopmental set (p-value = 0.007).
BD is a heterogeneous disorder clinically, and a previous report of common variation in this cohort 12 found evidence for genetic heterogeneity between clinical subtypes of BD. This information, combined with CNV burden being a well-established component of SCZ genetic architecture 27 , led us to hypothesize that increased CNV burden may be present in BD subtypes with high clinical similarity to SCZ. To test this hypothesis, we first sought to determine if CNV burden differed between BD subtypes (BD I n = 3,833, BD II n = 1,436, SAB n = 579) and controls (n = 6,383), as well as between BD subtypes compared to one another. Increased burden was seen in SAB compared to controls in all 3 of the primary burden classes evaluated, as well as compared to both BD I and BD II ( Table 2) . For one burden classnumber of CNVs with size over 500KB and frequency < 1% -SAB had higher burden compared to controls (p-value = 0.001), BD I (p-value = 3 x 10 -4 ; Figure 2a ) and BD II (p-value = 7 x 10 -4 ). We therefore elected to focus downstream CNV analyses on this class of burden.
Contribution of CNV burden and SCZ PRS to psychosis in BD
SCZ is the archetypal psychotic illness in current psychiatric classification systems 5 and increased CNV burden is a well-established component of its genetic architecture 27, 28 . Psychosis is also a prominent component of BD, and the diagnostic criteria differentiating BD subtypes (e.g., BD I, SAB) from one another and from SCZ relate to the co-occurrence of psychosis with mania 5,6 . The observed CNV burden in SABa diagnosis that requires most of the criteria of SCZ be metbeing absent in BD broadly prompted inquiry into whether CNV burden contributes to psychosis or to non-diagnostic clinical phenomena that differentiate SAB from other BD subtypes, and whether the same pattern is seen for common SCZ risk alleles. We stratified the ICCBD cases by the prominence of psychotic symptoms, correlating psychosis risk with both the CNV burden (number of CNVs with size over 500KB and frequency < 1%) and SCZ PRS 12, 32 . Cases were stratified into SAB (n = 579), BD I with psychosis (n = 2,676) and BD I without psychosis (n = 850). CNV burden was increased in SAB compared to BD I with and without psychosis (SAB rate = 0.116; BD I with psychosis rate = 0.069, p-value = 7.21 x 10 -4 ; BD I without psychosis rate = 0.067, p-value = 4.42 x 10 -4 ), but no difference was observed between BD I with and without psychosis (p-value = 0.88; Figure 2b) . SCZ PRS were higher in SAB compared to BD I with psychosis (p-value = 0.004) and in BD I with psychosis compared to BD I without psychosis (p-value = 0.005; Figure 2b) .
DISCUSSION
We observed no differences in the genome-wide burden of rare, large CNVs between BD cases and controls. This study had more than double the sample size used to initially identify CNV burden in SCZ, which is now well-established 27, 28 . This suggests that the lack of signal in BD is not due to lack of power. We were also able follow up on most nominally significant genome-wide CNV burden results that had previously been reported with respect to BD, reproducing the original analysis with respect to phenotypes compared and the cutoffs for CNV size and frequency used in the quality control procedures. Depending on the test, our case sample size represented an increase in case sample size from the original report of 3.74-fold to 28.71-fold ( Table 3) . We did not find strong support for any of the previous observations with respect to genome-wide CNV burden in BD. Taken together, the BD case-control analyses presented here strongly suggest that rare CNV burden is not a feature of BD when treated as a single diagnostic entity.
Individuals with a diagnosis of BD comprise a clinically heterogeneous group, and the lack of CNV burden when BD is treated as a single diagnostic entity does not preclude a role of CNV burden in the pathogenesis of subsets of cases. Specifically, we hypothesized this may the case for individuals who present with psychotic symptoms in the absence of a major mood episode, given the known CNV burden in SCZ 27, 28 and the clinical overlap between SCZ and BD. Indeed, we found that cases with SABwho by definition experience psychosis both in the presence and absence of maniahave higher rates of large, rare CNVs compared to controls and other BD subtypes.
The diagnostic criteria differentiating BD I with psychosis, SAB and SCZ from one another relate to the prominence and timing of psychotic symptoms. Through deeper analyses comparing SAB and BD I, however, we found that CNV burden was unrelated to the presence of psychosis. This was in contrast to SCZ PRS, which were higher in SAB compared to BD I with psychosis, and higher in BD I with psychosis compared to BD I without psychosis. Taken together, these results suggest that common SNPs may contribute to psychotic symptoms whereas rare CNVs may contribute to other dimensions of clinical illness within individuals with severe psychotic conditions. In this way, rare CNVs may contribute to the clinical phenomena that differentiate diagnostic categories but are not part of formal diagnostic criteria. One possibility in this regard is that CNVs may influence risk for cognitive deficits, which are more prominent in SCZ compared to BD. CNVs in disorders characterized by prominent cognitive deficits affect cognition in the general population 33 , and it will be of interest in future work to test if CNV burden is increased in BD patients who show cognitive impairments akin to those seen in SCZ 42, 43 as might be suggested by recent family-based studies 44 . Another possibility is that CNV burden increases risk for spontaneous psychosis (i.e., the psychoses of SCZ and SAB) but not psychosis secondary to severe mental stress, which it can be argued is the mechanism underlying psychosis during mania. Future studies with deeper phenotyping should aim to test these and other hypotheses.
This study has important limitations. Diagnostic misclassification of SCZ cases with SAB is possible, and while unlikely could account for the observed PRS and CNV results. For several of these analyses, sample size is a critical consideration and, as our inability to replicate most of the previous findings with respect to CNVs in BD highlighted, caution must be taken to avoid over-interpreting the results of analyses of this size. Instead, we emphasize that these findings must be followed up in larger cohorts. If replicated, they would provide support for the notion that different classes of genetic variants contribute to different classes of symptomatology in mood and psychotic syndromes. It might then be fair to inquire whether the higher CNV burden in SCZ compared to BD may be evidence not that they comprise two biologically distinct disease entities, but rather that clinicians are more likely to diagnose SCZ when a particular clinical phenomenon is present (e.g., cognitive deficits, spontaneous psychosis). These unresolved questions highlight the need for a multiscale approach to the study of mental illness, whereby integrating high-dimensional molecular and clinical data from each patient at the scale that GWAS has shown can be achieved may facilitate the development of a data-driven taxonomy. Table 3 . Follow-up of previous reports of increased copy number variant burden in BD. Listed are all findings identified from manual curation of literature on rare copy number variant (CNV) burden in BD with a p-value below 0.05 in the original report. Details of the test performed in the original report that was reproduced in ICCBD are described in the test parameter fields and include the phenotypes compared, the definition of burden, and the filters applied for CNV frequency, type and size. Ratios were calculated as the burden in the first phenotype in the comparison field relative to the second phenotype. When the original report did not specify the CNV size studied all CNVs greater than 100KB were included in the ICCBD. Original reports where the test included either SCZ cases or BD trios could not be followed-up in the ICCBD, but are included in this table so as to consolidate all of the previously significant findings in rare CNV studies of BD. BD cases and controls in Bergen (2011) are part of the ICCBD, so for these follow-up tests only the ICCBD samples not in the original report were utilized. The controls in Grozeva (2010) comprise half of the BDRN controls in ICCBD; since there was no case overlap between these studies, all of these controls were included in the follow-up test in the ICCBD. The cases in Green (2015) are the BDRN cases in ICCBD, though these findings were not followed up in ICCBD as they involved SCZ cases. Early-onset was defined as less than 21 in Priebe (2012) and less than 18 in Zhang (2009) and ICCBD. Family history in Malhotra (2011) was defined as having a relative with bipolar disorder (I, II, SAB), schizophrenia, autism, MDD or intellectual disability; in ICCBD, it was defined as having a family member with any psychiatric history. Reported p-values for ICCBD are 1-sided from using 10,000 permutations to test for enrichment in the direction observed in the original report. Asterisks denote nominal significance observed in ICCBD. BD -bipolar disorder; CON -control; EO -early-onset bipolar disorder; FAM -bipolar disorder with a family history of psychiatric illness; SPOR -sporadic bipolar disorder (i.e., no family history of psychiatric illness); SCZ -schizophrenia; SING -singleton; CNV -copy number variant; SCZ -schizophrenia; NR -not reported; NA -not applicable; N -number of individuals for the groups listed in the comparison field b This study included the ICCBD SWEBIC Affymetrix cohort, thus our replication test excluded this cohort
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Test parameters
Original report ICCBD a Sample sizes approximated from earlier studies of the same cohort Figure 1 . Replication of previous reports of CNV burden in BD. Curation of literature on CNV burden in BD identified 36 instances where nominal association (p-value < 0.05) was reported. We were able to test 28 of these in the ICCBD. Plotted here are p-values in previous reports (x-axis) compared to the same test performed in ICCBD cohort (y-axis). There were 4 tests for which nominal significance was observed in the ICCBD data: (1) singleton deletions greater than 100KB in cases compared to controls, (2) proportion of individuals with a singleton deletion greater than 100KB in cases compared to controls, (3) singleton deletions greater than 100KB in early onset cases compared to controls, and (4) proportion of individuals with a singleton deletion greater than 100KB in early onset cases compared to controls. None of these observations surpassed multiple test correction for the 27 tests we followed up in our data. Figure 2 . Burden of rare CNVs (frequency < 1%) greater than 500KB in SAB compared to BD I. (a) Forest plot of CNV burden partitioned by site of collection, with the full ICCBD sample at the bottom. CNV burden is calculated by combining CNV deletions and duplications. The p-values presented here for burden tests used a logistic regression model predicting SAB-BD I status by CNV burden along with covariates. The odds ratio (OR) is the exponential of the logistic regression coefficient, and OR > 1 predicts increased SAB risk. (b) Comparison of BD and SAB to one another with respect to polygenic risk scores and CNV burden. Regression analyses were performed of phenotype (stratified by history of psychosis) on polygenic scores derived from a previous GWAS for SCZ (blue) and burden of CNVs with frequency less than 1% and size greater than 500KB (red). MDS components, study site and gender were used as covariates. The tstatistic plotted on the x-axis is the ratio of the coefficient of the polygenic score or CNV burden variable and its standard error from the generalized linear model regression equation. The direction of the plotted bars indicates higher CNV burden or PRS in the phenotype listed first in the y-axis label. The p-values for whether polygenic risk scores or CNV burden differed significantly between phenotypes are shown at the far right. ......................................................................................................................................... 1   PHENOTYPING .................................................................................................................................................. 2 Swedish Bipolar Cohort (SWEBIC) ................................................................................................................................ 2 Network (BDRN) ........................................................................................................... ........................................................................................................................................ 3 Accounting for platform differences in BDRN cases and controls .............................................................................. 3   Plate effects .................................................................................................................................................................... 3   SUPPLEMENTARY TABLES AND FIGURES........................................................................................................... 4   REFERENCES ...................................................................................................................................................... 6 Phenotyping Swedish Bipolar Cohort (SWEBIC) SWEBIC phenotype data is derived from 3 primary sources. The St. Göran Bipolar Project cohort performs phenotyping via psychiatrists (or residents in psychiatry) using a Swedish version of the Affective Disorder Evaluation that was employed in the STEP-BD study and which includes the SCID module for affective disorders. Other disorders are covered by the M.I.N.I. Neuropsychiatric interview (MINI). The BipoläR cohort is based on the Swedish quality assurance (QA) register. Phenotyping is performed by the registering physician in the QA register, and structured telephone interview is also conducted by research nurses. The Swedish study of bipolar disorder cohort (also called the "Schalling cohort") performs phenotyping of patients by nurses and doctors manually reviewing medical charts and documenting a health interview form. Across the collection sites, age of onset was assigned based on age of first symptoms (<12 years old, 12-24, >24) and age at first diagnosis (<12 years old, 12-17, 18-24, 25-40, >40).
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Contribution of rare copy number variants to bipolar disorder risk is limited to schizoaffective cases
Bipolar Disorder Research
Bipolar Disorder Research Network (BDRN)
Phenotyping strategies for the BDRN cases and controls have been previously reported 1 . In brief, case participants were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). Psychiatric and general practice case-notes, where available, were also reviewed. On the basis of these data, best-estimate lifetime diagnoses were made according to DSM-IV criteria, and key clinical variables were rated such as age at onset. In cases where there was doubt, diagnostic and clinical ratings were made by at least two members of the research team blind to each other's rating. Age of onset was assigned based on age at first impairment (<12 years old, 12-17, 18-24, 25-40, >40) and age at first symptoms (<12 years old, 12-17, 18-24, 25-40, >40).
Genomic Psychiatry Consortium (GPC)
A comprehensive description of the phenotype data collection procedures for the GPC cohort has been previously published 2 . In brief, GPC cases and controls were collected via the University of Southern California healthcare system. Using a combination of focused, direct interviews and data extraction from medical records, diagnoses and sub-phenotypes were established using the OPCRIT 3 . Age and gender-matched controls were ascertained from the University of Southern California health system and assessed using a validated screening instrument and medical records. Subphenotypes from the GPC included in this report include family history, age of onset, history of psychosis, and clinical course. Age of onset was assigned based on age of first impairment (<12 years old, 12-17, 18-24, 25-40, >40).
Inter-site phenotypic comparisons
As previously reported 1 , we established a Phenotype Committee including at least 1 trained clinician from each participating site in order to assess the comparability of phenotypic classification across ICCBD cohorts. Each site contributed a set of notes from cases and from individuals that did not meet criteria for bipolar disorder but did meet criteria for related mood or psychotic disorders (also known as distractors). The notes were compiled in such a way as to keep them blinded with respect to case/distractor status. Each record included the full de-identified and finalized set of diagnostic data that were used by the sites' trained clinicians to evaluate diagnosis. Each of the Phenotype Committee members provided independent ratings of the primary variable (case vs. distractor) by reviewing the records. A quantitative analysis was conducted to determine the degree to which the committee members agree with diagnoses made by the trained clinicians. The inter-rater reliability was assessed using Fleiss' Kappa statistic for multiple raters (κ = 0.72 for the primary diagnostic variable). 
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